Status:
COMPLETED
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations
Lead Sponsor:
AstraZeneca
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
40-85 years
Phase:
PHASE3
Brief Summary
Phase 3 study to evaluate the efficacy and safety of a benralizumab in patients with moderate to very severe COPD with a history of frequent COPD exacerbations and elevated peripheral blood eosinophil...
Eligibility Criteria
Inclusion
- Provision of informed consent
- Age 40 to 85 years
- Male and/or female.
- Current or former smoker with a tobacco history of ≥10 pack-years.
- History of moderate to very severe COPD with a post-bronchodilator FEV1/FVC\<0.70 and FEV1 ≤65% of predicted normal value.
- Documented history of 2 or more COPD exacerbations that required treatment with systemic corticosteroids and/or hospitalization within 52 weeks prior to enrollment.
- Exacerbations treated with antibiotics alone are excluded unless accompanied by treatment with systemic corticosteroids and/or hospitalization.
- Hospitalization is defined as an inpatient admission ≥24 hours
- Previous exacerbations should be confirmed to have occurred while on stable triple therapy for COPD.
- At least one qualifying COPD exacerbation should occur while on stable uninterrupted triple therapy prior to enrolment.
- Documented use of triple (ICS/LABA/LAMA) background therapy for COPD for ≥3 months immediately prior to enrollment.
- Treatment with at least double inhaled therapy containing ICS (e.g. ICS/LABA or ICS/LAMA) for the remaining of 52 weeks prior to enrolment. Use of LABA/LAMA is allowed if ICS cannot be tolerated.
- ICS in a dose approved for COPD or equivalent to ≥250 mcg of fluticasone propionate daily.
- Total cumulative duration of not being on double or triple background therapy must not exceed 2 months.
- Stable therapy/doses for the last 3 months prior to randomization.
- Blood eosinophil count ≥300/μL at screening and documented historical eosinophil count of ≥150/μL within 52 weeks of enrollment (or repeated testing during run-in).
- CAT total score ≥15 at Visit 1.
- Negative pregnancy test for females of childbearing potential (WOCBP) at Visit 1.
- Women of childbearing potential (WOCBP) must agree to use a highly effective method of birth control from enrollment throughout the study and within 12 weeks after last dose of IP.
- Women not of childbearing potential are defined as women who are either permanently sterilized or postmenopausal (confirmed by FSH test for women \<50 years).
Exclusion
- Clinically important pulmonary disease other than COPD
- Current diagnosis of asthma, prior history of asthma or asthma-COPD overlap according to GINA/GOLD. Childhood history of asthma is allowed and defined as asthma diagnosed and resolved before the age of 18.
- Radiological findings of a respiratory disease other than COPD contributing to respiratory symptoms. Solitary pulmonary nodules without appropriate follow up or findings of acute infection.
- Another pulmonary or systemic disease associated with elevated peripheral eosinophil counts.
- Any unstable disorder that could affect patient safety, study findings or the patient's ability to complete the study.
- Any clinically significant abnormal findings in physical examination, vital signs, ECG, laboratory tests could affect patient safety, study findings or the patient's ability to complete the study.
- Cor pulmonale and/or right ventricular failure.
- Long-term treatment with oxygen \>4.0 L/min and/or oxyhemoglobin saturation \<89% while breathing supplemental oxygen.
- Use of any non-invasive positive pressure ventilation device (NIPPV). Note: use of CPAP for Sleep Apnea Syndrome is allowed.
- Known immunodeficiency disorder, including positive HIV-1/2 testing.
- Active liver disease. Chronic stable hepatitis B and C (including positive HBsAg or hepatitis C antibody testing), or other stable chronic liver disease are acceptable.
- ALT or AST ≥3 times the upper limit of normal, confirmed by repeated testing during the run-in period.
- Helminth parasitic infection within 24 weeks prior to enrollment, not treated or failed to respond to standard of care therapy.
- Alcohol or drug abuse within the past year, which may compromise the study data.
- Malignancy, current or within the past 5 years, except for adequately treated non invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma-in-situ treated with apparent success more than 1 year prior to Visit 1. Suspected malignancy or undefined neoplasms.
- Evidence of active tuberculosis, as judged by investigator. Patients with a recent (within 2 years) first-time or newly positive PPD or Quantiferon test need to complete an appropriate course of treatment before enrollment. Evaluation will be according to the local standard of care.
- Participation, or planned participation, in intensive COPD rehabilitation program (maintenance phase of a rehabilitation is allowed).
- History of surgical or endoscopic lung volume reduction within the 6 months prior to enrollment. History of partial or total lung resection (single lobe or segmentectomy is acceptable).
- Scheduled major surgical procedure during the study. Minor elective procedures are allowed.
- History of anaphylaxis to any biologic therapy or vaccine.
- Receipt of blood products or immunoglobulins within 30 days prior to randomization.
- Receipt of marketed or investigational biologic product within 4 months or 5 half-lives prior to randomization, whichever is longer. Exception: Patients on stable therapy for 3 months before randomization who intend to stay on treatment throughout the study with marketed biologic products that are not likely to interfere with the safety assessment and/or efficacy of benralizumab, for example, for the treatment of osteoporosis, migraine, pain, diabetes, obesity, ocular, cardiovascular, or metabolic diseases, can participate in the study.
- Receipt of live attenuated vaccines 30 days prior to randomization.
- Chronic use of immunosuppressive medication or expected need for chronic use during the study.
- Chronic use of antibiotics if duration of treatment is \<9 months prior to randomization. Chronic macrolide or other antibiotic therapy is allowed provided the patient has been on stable dose/regimen for ≥9 months prior to randomization and has had ≥2 COPD exacerbations while on stable therapy.
- Receipt of any investigational non-biologic product within 30 days or 5 half-lives prior to enrollment.
- Receipt of benralizumab within 12 months prior to enrollment.
- Known history of allergy or reaction to any component of the IP formulation.
Key Trial Info
Start Date :
August 26 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 28 2025
Estimated Enrollment :
689 Patients enrolled
Trial Details
Trial ID
NCT04053634
Start Date
August 26 2019
End Date
July 28 2025
Last Update
August 19 2025
Active Locations (343)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Surprise, Arizona, United States, 85374
2
Research Site
Little Rock, Arkansas, United States, 72209
3
Research Site
Los Angeles, California, United States, 90033
4
Research Site
Los Angeles, California, United States, 90048